Drug
TD 1607
TD 1607: highest development phase Phase 1, developed by Theravance Biopharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Theravance Biopharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| TD-1607 NCT01791049 | Phase 1 | Serious Infections Due to Known or Suspected Gram-positive Pathogens |
Latest
No recent events.
Follow TD 1607 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.